Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045539 · ClinicalTrials.gov registry record · Phase 2
Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
A Phase 2 study, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00045539: Completed Phase 2 study, sponsored by New Approaches to Brain Tumor Therapy Consortium.
NCT00045539 is a Phase 2 study that has completed, run by New Approaches to Brain Tumor Therapy Consortium. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045539, a Phase 2 study, has completed, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as methotrexate and thiotepa, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining methotrexate with thiotepa in treating patients who have newly-diagnosed primary CNS lymphoma.
Interventions
- DRUG leucovorin calcium
- DRUG methotrexate
- DRUG thiotepa
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
What the finished NCT00045539 record still lists
NCT00045539 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which leucovorin calcium is the first listed.
NCT00045539 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00045539 about?
NCT00045539 is a clinical study titled "Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma". RATIONALE: Drugs used in chemotherapy, such as methotrexate and thiotepa, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining methotrexate with ...
What is the current status of trial NCT00045539?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-10. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00045539?
The interventions under investigation include: leucovorin calcium (DRUG), methotrexate (DRUG), thiotepa (DRUG).
Who is sponsoring clinical trial NCT00045539?
This trial is sponsored by New Approaches to Brain Tumor Therapy Consortium, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia